Skip to main content
Top
Published in: Drugs & Aging 3/2011

01-03-2011 | Original Research Article

Effects of Anticholinergic Drugs on Verbal Episodic Memory Function in the Elderly

A Retrospective, Cross-Sectional Study

Authors: Dr Marie-Pierre Fortin, Isabelle Rouch, Virginie Dauphinot, Claire Gédéon, Stella Genthon, Marc Bonnefoy, Pierre Krolak-Salmon

Published in: Drugs & Aging | Issue 3/2011

Login to get access

Abstract

Background

An increasing number of medications that are frequently prescribed to elderly patients have been identified as having weak but definite anticholinergic properties. Few epidemiological studies have evaluated the impact of these drugs on verbal episodic memory using sensitive and specific neuropsychological testing in an elderly population presenting with cognitive impairment.

Objectives

The aim of this study was to assess the effect of drugs with anticholinergic properties on verbal episodic memory function in elderly patients presenting for memory evaluation.

Study Design

We performed a retrospective, cross-sectional study that included 134 consecutive elderly outpatients who attended the daycare memory unit of Centre Hospitalier Sud, Lyon, France. We searched the MEDLINE database (1973–2008) to identify drugs with anticholinergic properties. All drugs with well known anticholinergic activity, mild reported anticholinergic effects or in vitro anticholinergic activity were included in the study.

Measurements

We used the Free and Cued Selective Reminding (FCSR) test to evaluate verbal episodic memory.

Results

The mean±SD number of drugs with anticholinergic properties taken by the subjects was 0.64±0.82. Fifty percent of the subjects (n = 67) had a prescription for at least one drug with anticholinergic properties and 16% (n = 21) had a prescription for two or more. Drugs with anticholinergic properties most frequently prescribed in our cohort were cardiovascular (furosemide, hydrochlorothiazide, digoxin), antidepressant (paroxetine, sertraline, fluoxetine) and antispasmodic (oxybutynin chloride) drugs. The number of drugs with anticholinergic properties that subjects were taking was associated with reduced performance on tasks that assessed verbal memory (p < 0.05). Neuropsychological test batteries revealed a significant unfavourable effect of use of drugs with anticholinergic activity on episodic verbal memory. Tests evaluating other cognitive functions were not affected by use of drugs with anticholinergic activity. These associations remained following multivariate analysis adjusting for age, sex, education level, number of anticholinergic drugs, number of co-morbidities, diagnosis, behavioural symptoms and depressive symptoms.

Conclusion

Clinicians should assess the current use of drugs with anticholinergic properties in the elderly, particularly in patients presenting for memory evaluation. In such cases, use of other therapeutic alternatives should be considered.
Literature
2.
go back to reference Ramaroson H, Helmer C, Barberger-Gateau P, et al. Prevalence of dementia and Alzheimer’s disease among subjects aged 75 years or over: updated results of the PAQUID cohort. Rev Neurol (Paris) 2003 Apr; 159(4): 405–11 Ramaroson H, Helmer C, Barberger-Gateau P, et al. Prevalence of dementia and Alzheimer’s disease among subjects aged 75 years or over: updated results of the PAQUID cohort. Rev Neurol (Paris) 2003 Apr; 159(4): 405–11
3.
go back to reference DeKosky ST. Neurobiology and molecular biology of Alzheimer’s disease. Rev Neurol 2002 Oct 16–31; 35(8): 752–60PubMed DeKosky ST. Neurobiology and molecular biology of Alzheimer’s disease. Rev Neurol 2002 Oct 16–31; 35(8): 752–60PubMed
4.
go back to reference Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry 2003 Feb; 60(2): 198–203PubMedCrossRef Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry 2003 Feb; 60(2): 198–203PubMedCrossRef
5.
go back to reference Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008 Mar 10; 168(5): 508–13PubMedCrossRef Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008 Mar 10; 168(5): 508–13PubMedCrossRef
6.
go back to reference Tune LE. Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychiatry 2000 Apr; 5(2): 149–53PubMed Tune LE. Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychiatry 2000 Apr; 5(2): 149–53PubMed
7.
go back to reference Masoudi FA, Baillie CA, Wang Y, et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998–2001. Arch Intern Med 2005 Oct 10; 165(18): 2069–76PubMedCrossRef Masoudi FA, Baillie CA, Wang Y, et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998–2001. Arch Intern Med 2005 Oct 10; 165(18): 2069–76PubMedCrossRef
8.
go back to reference Lechevallier-Michel N, Molimard M, Dartigues JF, et al. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID study. Br J Clin Pharmacol 2005 Feb; 59(2): 143–51PubMedCrossRef Lechevallier-Michel N, Molimard M, Dartigues JF, et al. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID study. Br J Clin Pharmacol 2005 Feb; 59(2): 143–51PubMedCrossRef
9.
go back to reference Cao YJ, Mager DE, Simonsick EM, et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther 2008 Mar; 83(3): 422–9PubMedCrossRef Cao YJ, Mager DE, Simonsick EM, et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther 2008 Mar; 83(3): 422–9PubMedCrossRef
10.
go back to reference Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006 Feb 25; 332(7539): 455–9PubMedCrossRef Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006 Feb 25; 332(7539): 455–9PubMedCrossRef
11.
go back to reference Cancelli I, Valentinis L, Merlino G, et al. Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer’s disease. Clin Pharmacol Ther 2008 Jul; 84(1): 63–8PubMedCrossRef Cancelli I, Valentinis L, Merlino G, et al. Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer’s disease. Clin Pharmacol Ther 2008 Jul; 84(1): 63–8PubMedCrossRef
12.
go back to reference Uusvaara J, Pitkala KH, Tienari PJ, et al. Association between anticholinergic drugs and apolipoprotein E epsilon4 allele and poorer cognitive function in older cardiovascular patients: a cross-sectional study. J Am Geriatr Soc 2009 Mar; 57(3): 427–31PubMedCrossRef Uusvaara J, Pitkala KH, Tienari PJ, et al. Association between anticholinergic drugs and apolipoprotein E epsilon4 allele and poorer cognitive function in older cardiovascular patients: a cross-sectional study. J Am Geriatr Soc 2009 Mar; 57(3): 427–31PubMedCrossRef
13.
go back to reference Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993 Jul–Aug; 3(4): 335–48PubMedCrossRef Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993 Jul–Aug; 3(4): 335–48PubMedCrossRef
14.
go back to reference Rudd KM, Raehl CL, Bond CA, et al. Methods for assessing drug-related anticholinergic activity. Pharmacotherapy 2005 Nov; 25(11): 1592–601PubMedCrossRef Rudd KM, Raehl CL, Bond CA, et al. Methods for assessing drug-related anticholinergic activity. Pharmacotherapy 2005 Nov; 25(11): 1592–601PubMedCrossRef
15.
go back to reference Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000 Sep; 93(9): 457–62PubMed Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000 Sep; 93(9): 457–62PubMed
16.
go back to reference Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry 2003 Jul–Aug; 11(4): 458–61PubMed Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry 2003 Jul–Aug; 11(4): 458–61PubMed
17.
go back to reference Thienhaus OJ, Allen A, Bennett JA, et al. Anticholinergic serum levels and cognitive performance. Eur Arch Psychiatry Clin Neurosci 1990; 240(1): 28–33PubMedCrossRef Thienhaus OJ, Allen A, Bennett JA, et al. Anticholinergic serum levels and cognitive performance. Eur Arch Psychiatry Clin Neurosci 1990; 240(1): 28–33PubMedCrossRef
19.
go back to reference Minzenberg MJ, Poole JH, Benton C, et al. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004 Jan; 161(1): 116–24PubMedCrossRef Minzenberg MJ, Poole JH, Benton C, et al. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004 Jan; 161(1): 116–24PubMedCrossRef
20.
go back to reference Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008 May 26; 56(7): 1333–41PubMedCrossRef Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008 May 26; 56(7): 1333–41PubMedCrossRef
21.
go back to reference Snyder S, Greenberg D, Yamamura HI. Antischizophrenic drugs and brain cholinergic receptors: affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 1974 Jul; 31(1): 58–61PubMedCrossRef Snyder S, Greenberg D, Yamamura HI. Antischizophrenic drugs and brain cholinergic receptors: affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 1974 Jul; 31(1): 58–61PubMedCrossRef
22.
go back to reference Richelson E. Pharmacology of antidepressants: characteristics of the ideal drug. Mayo Clin Proc 1994 Nov; 69(11): 1069–81PubMedCrossRef Richelson E. Pharmacology of antidepressants: characteristics of the ideal drug. Mayo Clin Proc 1994 Nov; 69(11): 1069–81PubMedCrossRef
23.
go back to reference Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 Nov; 12(3): 189–98PubMedCrossRef Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 Nov; 12(3): 189–98PubMedCrossRef
24.
go back to reference Barbeau E, Didic M, Tramoni E, et al. Evaluation of visual recognition memory in MCI patients. Neurology 2004 Apr 27; 62(8): 1317–22PubMedCrossRef Barbeau E, Didic M, Tramoni E, et al. Evaluation of visual recognition memory in MCI patients. Neurology 2004 Apr 27; 62(8): 1317–22PubMedCrossRef
25.
go back to reference Deloche GeH D. Test de dénomination orale d’images DO80. Paris: INSERM, 1997 Deloche GeH D. Test de dénomination orale d’images DO80. Paris: INSERM, 1997
26.
go back to reference Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958; 8: 271–6 Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958; 8: 271–6
27.
go back to reference Cardebat D, Doyon B, Puel M, et al. Formal and semantic lexical evocation in normal subjects: performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg 1990; 90(4): 207–17PubMed Cardebat D, Doyon B, Puel M, et al. Formal and semantic lexical evocation in normal subjects: performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg 1990; 90(4): 207–17PubMed
28.
go back to reference Grober E, Buschke H, Crystal H, et al. Screening for dementia by memory testing. Neurology 1988 Jun; 38(6): 900–3PubMedCrossRef Grober E, Buschke H, Crystal H, et al. Screening for dementia by memory testing. Neurology 1988 Jun; 38(6): 900–3PubMedCrossRef
29.
go back to reference Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: a dose-response study. Arch Gen Psychiatry 1987 May; 44(5): 418–26PubMedCrossRef Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: a dose-response study. Arch Gen Psychiatry 1987 May; 44(5): 418–26PubMedCrossRef
30.
go back to reference Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008 Dec; 56(12): 2203–10PubMedCrossRef Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008 Dec; 56(12): 2203–10PubMedCrossRef
31.
go back to reference Carriere I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med 2009 Jul 27; 169(14): 1317–24PubMedCrossRef Carriere I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med 2009 Jul 27; 169(14): 1317–24PubMedCrossRef
Metadata
Title
Effects of Anticholinergic Drugs on Verbal Episodic Memory Function in the Elderly
A Retrospective, Cross-Sectional Study
Authors
Dr Marie-Pierre Fortin
Isabelle Rouch
Virginie Dauphinot
Claire Gédéon
Stella Genthon
Marc Bonnefoy
Pierre Krolak-Salmon
Publication date
01-03-2011
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 3/2011
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/11586580-000000000-00000

Other articles of this Issue 3/2011

Drugs & Aging 3/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.